The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine-Global Market Insights and Sales Trends 2024
Synopsis
DTaP (also DTPa and TDaP) is a combined vaccine against diphtheria, tetanus, and pertussis, in which the pertussis component is acellular. This is in contrast to whole-cell, inactivated DTP (aka DTwP). The acellular vaccine uses selected antigens of the pertussis pathogen to induce immunity. Because it uses fewer antigens than the whole cell vaccines, it is considered safer, but it is also more expensive. Recent research suggests that the DTP vaccine is more effective than DTaP in conferring immunity; this is because DTaP's narrower antigen base is less effective against current pathogen strains.
The global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine in various end use industries. The expanding demands from the Adult and Pediatric, are propelling Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market. Immune DTaP Vaccine, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Therapy DTaP Vaccine segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine covered in this report include Sanofi Pasteur, GlaxoSmithKline, Protein Sciences Corporation, Novartis AG, Seqirus, Merck Sharp & Dohme Corp, Astellas Pharma US, Pfizer Inc and Johnson & Johnson, etc.
The global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Sanofi Pasteur
GlaxoSmithKline
Protein Sciences Corporation
Novartis AG
Seqirus
Merck Sharp & Dohme Corp
Astellas Pharma US
Pfizer Inc
Johnson & Johnson
Lanzhou Institute of Biological Products Co., Ltd
AstraZeneca
Emergent BioSolutions Inc
Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market, Segment by Type:
Immune DTaP Vaccine
Therapy DTaP Vaccine
Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market, by Application
Adult
Pediatric
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
DTaP (also DTPa and TDaP) is a combined vaccine against diphtheria, tetanus, and pertussis, in which the pertussis component is acellular. This is in contrast to whole-cell, inactivated DTP (aka DTwP). The acellular vaccine uses selected antigens of the pertussis pathogen to induce immunity. Because it uses fewer antigens than the whole cell vaccines, it is considered safer, but it is also more expensive. Recent research suggests that the DTP vaccine is more effective than DTaP in conferring immunity; this is because DTaP's narrower antigen base is less effective against current pathogen strains.
The global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine in various end use industries. The expanding demands from the Adult and Pediatric, are propelling Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market. Immune DTaP Vaccine, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Therapy DTaP Vaccine segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine covered in this report include Sanofi Pasteur, GlaxoSmithKline, Protein Sciences Corporation, Novartis AG, Seqirus, Merck Sharp & Dohme Corp, Astellas Pharma US, Pfizer Inc and Johnson & Johnson, etc.
The global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Sanofi Pasteur
GlaxoSmithKline
Protein Sciences Corporation
Novartis AG
Seqirus
Merck Sharp & Dohme Corp
Astellas Pharma US
Pfizer Inc
Johnson & Johnson
Lanzhou Institute of Biological Products Co., Ltd
AstraZeneca
Emergent BioSolutions Inc
Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market, Segment by Type:
Immune DTaP Vaccine
Therapy DTaP Vaccine
Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine market, by Application
Adult
Pediatric
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Overview
1.1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Overview
1.2 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Segment by Type
1.2.1 Immune DTaP Vaccine
1.2.2 Therapy DTaP Vaccine
1.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Type
1.3.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Overview by Type (2018-2029)
1.3.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Historic Market Size Review by Type (2018-2023)
1.3.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Breakdown by Type (2018-2023)
1.4.2 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Breakdown by Type (2018-2023)
2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Competition by Company
2.1 Global Top Players by Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (2018-2023)
2.2 Global Top Players by Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Revenue (2018-2023)
2.3 Global Top Players by Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Price (2018-2023)
2.4 Global Top Manufacturers Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Manufacturing Base Distribution, Sales Area, Product Type
2.5 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Competitive Situation and Trends
2.5.1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine as of 2022)
2.7 Date of Key Manufacturers Enter into Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market
2.8 Key Manufacturers Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Status and Outlook by Region
3.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Historic Market Size by Region
3.2.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume by Region (2018-2023)
3.2.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value by Region (2018-2023)
3.2.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Forecasted Market Size by Region
3.3.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume by Region (2024-2029)
3.3.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value by Region (2024-2029)
3.3.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine by Application
4.1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Segment by Application
4.1.1 Adult
4.1.2 Pediatric
4.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size by Application
4.2.1 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Overview by Application (2018-2029)
4.2.2 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Historic Market Size Review by Application (2018-2023)
4.2.3 Global Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Breakdown by Application (2018-2023)
4.3.2 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales Breakdown by Application (2018-2023)
5 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine by Country
5.1 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Historic Market Size by Country
5.1.1 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume by Country (2018-2023)
5.1.3 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value by Country (2018-2023)
5.2 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Forecasted Market Size by Country
5.2.1 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume by Country (2024-2029)
5.2.2 North America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value by Country (2024-2029)
6 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine by Country
6.1 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Historic Market Size by Country
6.1.1 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume by Country (2018-2023)
6.1.3 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value by Country (2018-2023)
6.2 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Forecasted Market Size by Country
6.2.1 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume by Country (2024-2029)
6.2.2 Europe Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value by Country (2024-2029)
7 Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine by Region
7.1 Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Historic Market Size by Region
7.1.1 Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Forecasted Market Size by Region
7.2.1 Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value by Region (2024-2029)
8 Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine by Country
8.1 Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Historic Market Size by Country
8.1.1 Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume by Country (2018-2023)
8.1.3 Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value by Country (2018-2023)
8.2 Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Forecasted Market Size by Country
8.2.1 Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume by Country (2024-2029)
8.2.2 Latin America Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value by Country (2024-2029)
9 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine by Country
9.1 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Historic Market Size by Country
9.1.1 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Forecasted Market Size by Country
9.2.1 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Sanofi Pasteur
10.1.1 Sanofi Pasteur Company Information
10.1.2 Sanofi Pasteur Introduction and Business Overview
10.1.3 Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Sanofi Pasteur Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Products Offered
10.1.5 Sanofi Pasteur Recent Development
10.2 GlaxoSmithKline
10.2.1 GlaxoSmithKline Company Information
10.2.2 GlaxoSmithKline Introduction and Business Overview
10.2.3 GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.2.4 GlaxoSmithKline Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Products Offered
10.2.5 GlaxoSmithKline Recent Development
10.3 Protein Sciences Corporation
10.3.1 Protein Sciences Corporation Company Information
10.3.2 Protein Sciences Corporation Introduction and Business Overview
10.3.3 Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Protein Sciences Corporation Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Products Offered
10.3.5 Protein Sciences Corporation Recent Development
10.4 Novartis AG
10.4.1 Novartis AG Company Information
10.4.2 Novartis AG Introduction and Business Overview
10.4.3 Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Novartis AG Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Products Offered
10.4.5 Novartis AG Recent Development
10.5 Seqirus
10.5.1 Seqirus Company Information
10.5.2 Seqirus Introduction and Business Overview
10.5.3 Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Seqirus Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Products Offered
10.5.5 Seqirus Recent Development
10.6 Merck Sharp & Dohme Corp
10.6.1 Merck Sharp & Dohme Corp Company Information
10.6.2 Merck Sharp & Dohme Corp Introduction and Business Overview
10.6.3 Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Merck Sharp & Dohme Corp Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Products Offered
10.6.5 Merck Sharp & Dohme Corp Recent Development
10.7 Astellas Pharma US
10.7.1 Astellas Pharma US Company Information
10.7.2 Astellas Pharma US Introduction and Business Overview
10.7.3 Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Astellas Pharma US Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Products Offered
10.7.5 Astellas Pharma US Recent Development
10.8 Pfizer Inc
10.8.1 Pfizer Inc Company Information
10.8.2 Pfizer Inc Introduction and Business Overview
10.8.3 Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.8.4 Pfizer Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Products Offered
10.8.5 Pfizer Inc Recent Development
10.9 Johnson & Johnson
10.9.1 Johnson & Johnson Company Information
10.9.2 Johnson & Johnson Introduction and Business Overview
10.9.3 Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.9.4 Johnson & Johnson Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Products Offered
10.9.5 Johnson & Johnson Recent Development
10.10 Lanzhou Institute of Biological Products Co., Ltd
10.10.1 Lanzhou Institute of Biological Products Co., Ltd Company Information
10.10.2 Lanzhou Institute of Biological Products Co., Ltd Introduction and Business Overview
10.10.3 Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.10.4 Lanzhou Institute of Biological Products Co., Ltd Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Products Offered
10.10.5 Lanzhou Institute of Biological Products Co., Ltd Recent Development
10.11 AstraZeneca
10.11.1 AstraZeneca Company Information
10.11.2 AstraZeneca Introduction and Business Overview
10.11.3 AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.11.4 AstraZeneca Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Products Offered
10.11.5 AstraZeneca Recent Development
10.12 Emergent BioSolutions Inc
10.12.1 Emergent BioSolutions Inc Company Information
10.12.2 Emergent BioSolutions Inc Introduction and Business Overview
10.12.3 Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Sales, Revenue and Gross Margin (2018-2023)
10.12.4 Emergent BioSolutions Inc Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Products Offered
10.12.5 Emergent BioSolutions Inc Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industrial Chain Analysis
11.4 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Dynamics
11.4.1 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Industry Trends
11.4.2 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Drivers
11.4.3 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Challenges
11.4.4 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Distributors
12.3 Diphtheria, Tetanus, and Pertussis (DTaP) Vaccine Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
